Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-10-04 | Travere Therapeutics, Inc. | LYONS GARY A
(Director) |
S | Common Stock | D | 40000 | $14.35 - $15.15 | $589,100 |
| 2024-10-04 | Travere Therapeutics, Inc. | LYONS GARY A
(Director) |
M | Common Stock | A | 40000 | $10.48 - $10.48 | $419,200 |
| 2024-09-30 | Travere Therapeutics, Inc. | Meckler Jeffrey A
(Director) |
S | Common Stock | D | 40000 | $14.06 - $14.06 | $562,324 |
| 2024-09-30 | Travere Therapeutics, Inc. | Meckler Jeffrey A
(Director) |
M | Common Stock | A | 40000 | $10.48 - $10.48 | $419,200 |
| 2024-09-09 | Travere Therapeutics, Inc. | ROTE WILLIAM E.
(SENIOR VICE PRESIDENT, R&D) |
S | Common Stock | D | 4387 | $11.52 - $11.52 | $50,538 |
| 2024-09-05 | Travere Therapeutics, Inc. | ROTE WILLIAM E.
(SENIOR VICE PRESIDENT, R&D) |
A | Common Stock | A | 6750 | $0.00 - $0.00 | $0 |
| 2024-09-09 | Travere Therapeutics, Inc. | REED ELIZABETH E
(SVP, GC & CORPORATE SECRETARY) |
S | Common Stock | D | 4387 | $11.52 - $11.52 | $50,538 |
| 2024-09-05 | Travere Therapeutics, Inc. | REED ELIZABETH E
(SVP, GC & CORPORATE SECRETARY) |
A | Common Stock | A | 6750 | $0.00 - $0.00 | $0 |
| 2024-09-09 | Travere Therapeutics, Inc. | Dube Eric M
(CHIEF EXECUTIVE OFFICER) |
S | Common Stock | D | 21125 | $11.52 - $11.52 | $243,360 |
| 2024-09-05 | Travere Therapeutics, Inc. | Dube Eric M
(CHIEF EXECUTIVE OFFICER) |
A | Common Stock | A | 32500 | $0.00 - $0.00 | $0 |
| 2024-09-09 | Travere Therapeutics, Inc. | Inrig Jula
(CHIEF MEDICAL OFFICER) |
S | Common Stock | D | 2191 | $11.52 - $11.52 | $25,240 |
| 2024-09-05 | Travere Therapeutics, Inc. | Inrig Jula
(CHIEF MEDICAL OFFICER) |
A | Common Stock | A | 6750 | $0.00 - $0.00 | $0 |
| 2024-09-09 | Travere Therapeutics, Inc. | Heerma Peter
(CHIEF COMMERCIAL OFFICER) |
S | Common Stock | D | 2191 | $11.52 - $11.52 | $25,240 |
| 2024-09-05 | Travere Therapeutics, Inc. | Heerma Peter
(CHIEF COMMERCIAL OFFICER) |
A | Common Stock | A | 6750 | $0.00 - $0.00 | $0 |
| 2024-09-09 | Travere Therapeutics, Inc. | Cline Christopher R.
(CHIEF FINANCIAL OFFICER) |
S | Common Stock | D | 2490 | $11.52 - $11.52 | $28,684 |
| 2024-09-05 | Travere Therapeutics, Inc. | Cline Christopher R.
(CHIEF FINANCIAL OFFICER) |
A | Common Stock | A | 6750 | $0.00 - $0.00 | $0 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |